enCas12Ultra mRNA (N1-Me-Pseudo UTP)

Catalog # U0872 Size 100 ug

Applications



Flow Cytometry

The enCas12Ultra gene-editing system can efficiently knockout both TRAC and CD7 genes in CD3+ T cells. The gene knockout efficiency, as determined by flow cytometry and sequencing, exceeds 90.0%.



编号	mRNA	Target gene	编辑效率(Tide%)
1	enCas12Ultra mRNA	TRAC	96.29
		CD70	94.90
		B2M	98.33
		CD7	95.93
		PD-1	91.40
		HLA-A	89.40
		CIITA	91.20
		AAVS1	91.90
		TTR	83.50
		mRosa26	93.19
		mdystX51	86.64
		mKrt17	85.20
2	spCas9 mRNA	B2M PC-g1	98.50
		TRAC PC-g4	86.40
		PD-1 PC-g1	95.00

In vitro Transcription

Following electroporation of enCas12Ultra mRNA + target-specific sgRNA into 293T cells, TIDE analysis showed that the gene editing efficiencies for genes such as TRAC, CD70, B2M, CD7, PD-1, HLA-A, CIITA and mRosa26 all exceeded 90.0%.

Specification

Product Description	The enCas12Ultra mRNA is used to express the enCas12Ultra protein. When used in combination w ith purified sgRNA, it canspecifically recognize and cleave double-stranded DNA (dsDNA) targets co ntaining the protospacer adjacent motif (PAM) sequence(5'-TTN), inducing double-strand breaks and producing sticky ends.
Theoretical MW (kDa)	1,472,977.6 g/mol
Form	Liquid
Concentration	5.0-5.5 mg/mL
Recommend Usage	The optimal working dilution should be determined by the end user.

Copyright © 2023 Abnova Corporation. All Rights Reserved.

Storage Buffer	1 mM sodium citrate buffer
Storage Instruction	Store at -20°C. Aliquot to avoid repeated freezing and thawing.

Applications

- Flow Cytometry

  The enCas12Ultra gene-editing system can efficiently knockout both TRAC and CD7 genes in CD3+ T cells. The gene knockout efficiency, as determined by flow cytometry and sequencing, exceeds 90.0%.

  Protocol Download

- In vitro Transcription

  Following electroporation of enCas12Ultra mRNA + target-specific sgRNA into 293T cells, TIDE analysis showed that the gene editing efficiencies for genes such as TRAC, CD70, B2M, CD7, PD-1, HLA-A, CIITA and mRosa26 all exceeded 90.0%.

Copyright © 2023 Abnova Corporation. All Rights Reserved.